| Canis lupus familiaris |
MDCK |
CC50 |
45.1 |
ug.mL-1 |
10.1016/S0960-894X(97)10154-8 |
| Canis lupus familiaris |
MDCK |
EC50 |
45.1 |
ug.mL-1 |
10.1016/S0960-894X(97)10154-8 |
| Cavia porcellus |
Cavia porcellus |
Contraction |
5.7 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Contraction |
6.3 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Contraction |
7.0 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Contraction |
13.2 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Contraction |
43.0 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Contraction |
109.2 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Inhibition |
-21.0 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Cavia porcellus |
Inhibition |
-18.1 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Kappa opioid receptor |
Ki |
2570.4 |
nM |
10.1021/jm010576e |
| Cavia porcellus |
Kappa opioid receptor |
Relative affinity |
3.2 |
% |
10.1021/jm010576e |
| Cavia porcellus |
Mu opioid receptor |
Ki |
72.44 |
nM |
10.1021/jm010576e |
| Cavia porcellus |
Mu opioid receptor |
Relative affinity |
95.8 |
% |
10.1021/jm010576e |
| Homo sapiens |
Alpha-1a adrenergic receptor |
Inhibition |
45.9 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1a adrenergic receptor |
Inhibition |
100.5 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1a adrenergic receptor |
Ki |
nan |
None |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1b adrenergic receptor |
Inhibition |
19.6 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1b adrenergic receptor |
Inhibition |
91.0 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1b adrenergic receptor |
Ki |
nan |
None |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1d adrenergic receptor |
Inhibition |
73.5 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1d adrenergic receptor |
Inhibition |
101.2 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-1d adrenergic receptor |
Ki |
41.7 |
nM |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2a adrenergic receptor |
Inhibition |
27.2 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2a adrenergic receptor |
Inhibition |
95.1 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2a adrenergic receptor |
Ki |
nan |
None |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2b adrenergic receptor |
Inhibition |
8.5 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2b adrenergic receptor |
Inhibition |
79.9 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2b adrenergic receptor |
Ki |
nan |
None |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Alpha-2c adrenergic receptor |
Ki |
nan |
None |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Cytochrome P450 2D6 |
Ki |
2800.0 |
nM |
10.1021/acs.jnatprod.0c01163 |
| Homo sapiens |
Delta opioid receptor |
Inhibition |
8.6 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Delta opioid receptor |
Inhibition |
31.4 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Delta opioid receptor |
Ki |
2884.03 |
nM |
10.1021/jm010576e |
| Homo sapiens |
Delta opioid receptor |
Ki |
nan |
None |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Delta opioid receptor |
Relative affinity |
1.0 |
% |
10.1021/jm010576e |
| Homo sapiens |
HeLa |
Activity |
nan |
None |
10.1021/acs.jnatprod.8b00324 |
| Homo sapiens |
HepG2 |
Activity |
nan |
None |
10.1021/acs.jnatprod.8b00324 |
| Homo sapiens |
HT-29 |
Activity |
nan |
None |
10.1021/acs.jnatprod.8b00324 |
| Homo sapiens |
Kappa opioid receptor |
Inhibition |
16.7 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Kappa opioid receptor |
Inhibition |
59.4 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Kappa opioid receptor |
Ki |
1910.0 |
nM |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
MCF7 |
Activity |
nan |
None |
10.1021/acs.jnatprod.8b00324 |
| Homo sapiens |
Mu opioid receptor |
Inhibition |
39.6 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Mu opioid receptor |
Inhibition |
96.8 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Mu opioid receptor |
Ki |
118.0 |
nM |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Mu opioid receptor |
Ki |
1910.0 |
nM |
10.1021/acs.jnatprod.0c01055 |
| Homo sapiens |
Nociceptin receptor |
Inhibition |
-1.3 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Nociceptin receptor |
Inhibition |
27.0 |
% |
10.1021/acs.jmedchem.9b01465 |
| Homo sapiens |
Serotonin 1a (5-HT1a) receptor |
Activity |
2.5 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 1a (5-HT1a) receptor |
Activity |
77.3 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 2a (5-HT2a) receptor |
Activity |
-6.8 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 2a (5-HT2a) receptor |
Activity |
28.7 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 2b (5-HT2b) receptor |
Activity |
14.8 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 2b (5-HT2b) receptor |
Activity |
76.3 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 2c (5-HT2c) receptor |
Activity |
2.5 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 2c (5-HT2c) receptor |
Activity |
3.8 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 3a (5-HT3a) receptor |
Activity |
6.2 |
% |
10.1021/acs.jmedchem.1c00726 |
| Homo sapiens |
Serotonin 3a (5-HT3a) receptor |
Activity |
6.8 |
% |
10.1021/acs.jmedchem.1c00726 |
| Human immunodeficiency virus 1 |
Human immunodeficiency virus type 1 reverse transcriptase |
IC50 |
200.0 |
ug.mL-1 |
10.1021/np50073a012 |
| Rattus norvegicus |
Serotonin 1b (5-HT1b) receptor |
Activity |
-4.2 |
% |
10.1021/acs.jmedchem.1c00726 |
| Rattus norvegicus |
Serotonin 1b (5-HT1b) receptor |
Activity |
10.7 |
% |
10.1021/acs.jmedchem.1c00726 |
| None |
ADMET |
AUC |
8.2 |
ng.hr.mL-1 |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
AUC |
30.4 |
ng.hr.mL-1 |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
AUC/dose |
63.1 |
hr.kg.ng/ml/mg |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
AUC/dose |
138.8 |
hr.kg.ng/ml/mg |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
AUC/dose |
152.2 |
hr.kg.ng/ml/mg |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
CL |
4.1 |
mL.min-1.kg-1 |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
CL |
103.1 |
mL.min-1.kg-1 |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
Cmax |
4.885 |
nM |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Cmax |
8.413 |
nM |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Cmax/dose |
10.7 |
ng/ml |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Cmax/dose |
14.0 |
kg.ng/ml/mg |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Cmax/dose |
15.6 |
kg.ng/ml/mg |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
-4.6 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
-0.8 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
3.3 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
5.6 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
6.4 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
9.5 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
11.4 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug degradation |
14.2 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug recovery |
80.0 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Drug recovery |
90.0 |
% |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
ERH |
0.2 |
None |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
Fu |
0.02 |
None |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
Fu |
0.4 |
None |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
Kel |
0.1145 |
/min |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
Ratio |
2.4 |
None |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
T1/2 |
0.1017 |
hr |
10.1021/acs.jmedchem.9b01465 |
| None |
ADMET |
Tmax |
1.0 |
hr |
10.1021/acs.jnatprod.0c01163 |
| None |
ADMET |
Tmax |
3.1 |
hr |
10.1021/acs.jnatprod.0c01163 |